CONMED Soars 13.01% on Strong Q1 Earnings

On May 1, 2025, CONMED's stock surged by 13.01% in pre-market trading, reflecting a significant boost in investor confidence and market sentiment.

CONMED reported a strong start to 2025, with first-quarter sales reaching $321.3 million, marking a 2.9% year-over-year increase. This performance exceeded analyst estimates of $313.37 million, driven by a 4.2% increase in domestic revenue and a 1.2% growth in international revenue. The company's adjusted diluted net earnings per share (EPS) were $0.95, surpassing the analyst estimate of $0.80. However, the GAAP diluted EPS was $0.19, a decrease from $0.63 in the same period last year.

Despite these positive results, CONMED faces challenges such as currency headwinds, which are expected to impact revenue by approximately 50 to 70 basis points for the full year. The company has updated its full-year revenue expectations to be between $1.350 billion and $1.378 billion, and the full-year adjusted diluted net EPS is now expected to range from $4.45 to $4.60. Patrick J. Beyer, CONMED’s President and Chief Executive Officer, commented on the company's performance, stating that the strong start to 2025 positions them well to achieve their full-year guidance.

CONMED's strategic focus on strengthening operations and addressing currency headwinds is crucial for maintaining its competitive edge in the medical technology sector. As the company continues to navigate challenges and capitalize on growth opportunities, it remains a key player in the medical devices industry, attracting value investors seeking exposure to this sector.